Simcere Pharmaceutical

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Tuesday, November 21, 2023

These results follow the previously reported Stage 1 results of the trial, which met all primary and key secondary endpoints.

Key Points: 
  • These results follow the previously reported Stage 1 results of the trial, which met all primary and key secondary endpoints.
  • “This study demonstrated that rademikibart has a best-in-class potential, and if approved as a Q4W treatment, we believe could offer patients with AD a highly efficacious treatment with less frequent dosing than current approved treatments.
  • I’d like to thank the patients, their families, the clinical and manufacturing teams, and all of our vendors that were an integral part of this trial.
  • Patients that did not achieve EASI-50 (non-responders) were assigned to an open label Q2W rademikibart arm (n=86).

Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

Retrieved on: 
Thursday, December 21, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231221296013/en/
    Almirall HQ in Barcelona (Photo: Business Wire)
    ALM223 is a modified version of the protein IL-2 designed to selectively activate Regulatory T cells (Tregs).
  • It may therefore have potential to restore immune balance and prevent the immune cells from attacking the body’s own cells.
  • ALM223, previously referred to as SIM0278, had been developed by Simcere by utilizing their protein engineering platform.
  • Simcere also initiated the phase I development for the Chinese market in August 2023.

Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart

Retrieved on: 
Thursday, November 23, 2023

NANJING, China, Nov. 23, 2023 /PRNewswire/ -- On November 21, 2023, Simcere Pharmaceutical Group Limited ("Simcere") entered into an exclusive license and collaboration agreement (the "Agreement") with Connect Biopharma HongKong Limited ("Connect") in relation to Rademikibart, an innovative IL-4Rα monoclonal antibody.

Key Points: 
  • NANJING, China, Nov. 23, 2023 /PRNewswire/ -- On November 21, 2023, Simcere Pharmaceutical Group Limited ("Simcere") entered into an exclusive license and collaboration agreement (the "Agreement") with Connect Biopharma HongKong Limited ("Connect") in relation to Rademikibart, an innovative IL-4Rα monoclonal antibody.
  • Pursuant to the Agreement, Simcere obtains the exclusive rights in the development, manufacturing, and commercialization of Rademikibart for all indications in Greater China.
  • Connect will retain its rights outside Greater China and will complete the ongoing pivotal clinical trial for atopic dermatitis (AD) treatment and other ongoing clinical trials.
  • According to Simcere's announcement, this collaboration will further enhance its product portfolio in the autoimmune field and strengthen the synergistic effect in its commercialization efforts.

G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, November 1, 2023

Recognized $10.8 Million in Net COSELA Revenue: G1 recognized total revenues of $12.3 million for the third quarter of 2023.

Key Points: 
  • Recognized $10.8 Million in Net COSELA Revenue: G1 recognized total revenues of $12.3 million for the third quarter of 2023.
  • Vial volume grew 3% over the second quarter of 2023 despite the impact of an ongoing platinum-based chemotherapy shortage.
  • Ended the Third Quarter of 2023 with Cash, Cash Equivalents, and Marketable Securities of $94.4 Million.
  • Operating expenses for the third quarter of 2023 were $28.7 million, compared to $45.1 million for the third quarter of 2022.

Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer

Retrieved on: 
Monday, July 24, 2023

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Kevin R. Oliver as Senior Vice President, Chief Business Officer, effective July 10, 2023.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Kevin R. Oliver as Senior Vice President, Chief Business Officer, effective July 10, 2023.
  • Dr. Oliver will oversee all business development functions and will serve as a member of the company’s Executive Management Committee, reporting to Steve Davis, President and Chief Executive Officer of Acadia.
  • “We are pleased to announce Kevin’s appointment to lead our business development and partnering activities,” said Steve Davis, Acadia’s President and Chief Executive Officer.
  • Before joining Acadia, Dr. Oliver served as SVP, Head of Global Business Development & Licensing and Alliance Management, as well as Chief Operations Officer, U.S. and Europe at Simcere Pharmaceutical Group.

Monoclonal Antibodies: Competitive Landscape Report, 2023 Featuring Insights of Novartis, Gmax Biopharm, Omeros Corp, and Merck Sharp & Dohme Among ~180 Other Players - ResearchAndMarkets.com

Retrieved on: 
Monday, June 19, 2023

In March 2023, Shanghai - Jacos Pharmaceuticals (1167.HK) announced a clinical collaboration with Merck to evaluate the combination therapy of Si's CD73 monoclonal antibody JAB-BX102 and Merck's PD-1 inhibitor KEYTRUDA (pembrolizumab).

Key Points: 
  • In March 2023, Shanghai - Jacos Pharmaceuticals (1167.HK) announced a clinical collaboration with Merck to evaluate the combination therapy of Si's CD73 monoclonal antibody JAB-BX102 and Merck's PD-1 inhibitor KEYTRUDA (pembrolizumab).
  • This clinical study will evaluate the clinical effect of JAB-BX102 in combination with KEYTRUDA in advanced solid tumors.
  • Under the terms of the agreement, Merck will provide KEYTRUDA.
  • The transaction is expected to close in the first half of 2023, subject to customary closing conditions and regulatory clearances.

Simcere Pharmaceutical Group Announces Sponsored Research Agreement with Boston-based Mass General Brigham

Retrieved on: 
Monday, June 12, 2023

“The discoveries resulting from this agreement could further advance potentially game-changing technology to the front lines of care in three areas of rapid clinical advancement and high patient need -- neurology, oncology, and inflammation and immunology,” said Chris Coburn, chief innovation officer at Mass General Brigham. “We’re excited to collaborate with industry partners such as Simcere, whose expanding presence in the Boston area is reflective of our region’s continued growth as a biotech hub.”

Key Points: 
  • Simcere Pharmaceutical Group Limited (2096.HK) (Simcere) announced a Sponsored Research Agreement with Mass General Brigham.
  • Under the agreement up to eight research groups at Mass General Brigham will be funded on select projects over the course of two years.
  • By partnering with Mass General Brigham, Simcere gains access to cutting-edge research and leading clinical capabilities which will help accelerate the company's global R&D efforts.
  • "We believe that this Sponsored Research Agreement with Mass General Brigham represents a significant step forward in our efforts to develop innovative new treatment options for patients around the world,” said Zhou Gaobo, Chief Investment Officer, Simcere Pharmaceutical Group.

Insilico Medicine Appoints Michael Bayewitch as VP, Business Development and Strategy

Retrieved on: 
Monday, May 15, 2023

Abu Dhabi, May 15, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has appointed Michael Bayewitch, PhD, as Vice President (VP) of Business Development and Strategy.

Key Points: 
  • Abu Dhabi, May 15, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has appointed Michael Bayewitch, PhD, as Vice President (VP) of Business Development and Strategy.
  • Based on the U.S. West Coast, Dr. Bayewitch will work closely with Alex Zhavoronkov, PhD, founder and CEO, Feng Ren, PhD, Co-CEO and CSO,  and Michelle Chen, PhD, Chief Business Officer.
  • He is responsible for driving business development activities and developing attainable operation strategies to support Insilico's continued growth.
  • “As we witness the rapid development of the pharmaceutical industry and the dramatic innovation of AI technology, Insilico sees increasing demand for internal staff as more pipelines are entering the clinical stage,” said Dr. Alex Zhavoronkov, founder and CEO of Insilico Medicine.

Insilico Medicine Appoints Michael Bayewitch as VP, Business Development and Strategy

Retrieved on: 
Monday, May 15, 2023

Hong Kong, May 15, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has appointed Michael Bayewitch, PhD, as Vice President (VP) of Business Development and Strategy.

Key Points: 
  • Hong Kong, May 15, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has appointed Michael Bayewitch, PhD, as Vice President (VP) of Business Development and Strategy.
  • Based on the U.S. West Coast, Dr. Bayewitch will work closely with Alex Zhavoronkov, PhD, founder and CEO, Feng Ren, PhD, Co-CEO and CSO,  and Michelle Chen, PhD, Chief Business Officer.
  • He is responsible for driving business development activities and developing attainable operation strategies to support Insilico's continued growth.
  • “As we witness the rapid development of the pharmaceutical industry and the dramatic innovation of AI technology, Insilico sees increasing demand for internal staff as more pipelines are entering the clinical stage,” said Dr. Alex Zhavoronkov, founder and CEO of Insilico Medicine.

Insilico Medicine Appoints Michael Bayewitch as VP, Business Development and Strategy

Retrieved on: 
Monday, May 15, 2023

New York, May 15, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has appointed Michael Bayewitch, PhD, as Vice President (VP) of Business Development and Strategy.

Key Points: 
  • New York, May 15, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has appointed Michael Bayewitch, PhD, as Vice President (VP) of Business Development and Strategy.
  • Based on the West Coast, Dr. Bayewitch will work closely with Alex Zhavoronkov, PhD, founder and CEO, Feng Ren, PhD, Co-CEO and CSO,  and Michelle Chen, PhD, Chief Business Officer.
  • He is responsible for driving business development activities and developing attainable operation strategies to support Insilico's continued growth.
  • “As we witness the rapid development of the pharmaceutical industry and the dramatic innovation of AI technology, Insilico sees increasing demand for internal staff as more pipelines are entering the clinical stage,” said Dr. Alex Zhavoronkov, founder and CEO of Insilico Medicine.